Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. By Tsai et al. 2014

The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. By Dueregger et al. 2014 

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. By Sammon et al. 2014 

Is there any harm in using ADT as a first line treatment for PCa?

Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer. By Taguchi et al. 2014 

Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. By Taplin et al. 2014 

Lifestyle Changes for Improving Disease-specific Quality of Life in Sedentary Men on Long-term Androgen-Deprivation Therapy for Advanced Prostate Cancer: A Randomised Controlled Trial. By Bourke et al. 2014

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. By Denham et al. 2014

Functional and metabolic complications of androgen deprivation therapy. By Herrera-Caceres and Castillejos-Molina 2014 

Influence of Age on Incident Diabetes and Cardiovascular Disease Among Prostate Cancer Survivors Receiving Androgen Deprivation Therapy. By Morgans et al. 2014